CTIS2023-504257-12-00进行中（未招募）1 期
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis - 1366-0029
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial, Male or female who is = 18 (or who is of legal age in countries where that is greater than 18) and = 75 years old at screening, Clinical signs of CSPH as described by either one of the points below. Each trial patient must have a gastroscopy during the screening period or within 6 months prior to screening. (i) documented endoscopic proof of oesophageal varices and / or gastric varices at screening or within 6 months prior to screening (ii) documented endoscopic-treated oesophageal varices as preventative treatment, CSPH defined as baseline HVPG = 10 mmHg (measured at Visit 1c), based on a local interpretation of the pressure tracing, Diagnosis of compensated cirrhosis due to HCV, HBV, or NASH with or without T2DM. Diagnosis of cirrhosis must be based on histology (historical data is acceptable) or on clinical evidence of cirrhosis (e.g. platelet count < 150 x 109/L [150 x 103/µL], nodular liver surface on imaging or splenomegaly etc.) Diagnosis of NASH based on either i. Current or historic histological diagnosis of NASH OR steatosis OR ii. Clinical diagnosis of NASH based on historic or current imaging diagnosis of fatty liver (Fibroscan, US, MRI, CT) AND at least 2 current or historic comorbidities of the metabolic syndrome (overweight/obesity, T2DM, hypertension, hyperlipidemia), Willing and able to undergo HVPG measurements per protocol (based on Investigator judgement), If receiving statins must be on a stable dose for at least 3 months prior to screening, with no planned dose change throughout the trial, If receiving treatment with NSBBs or carvedilol must be on a stable dose for at least 1 month prior to screening, with no planned dose change throughout the trial, Further inclusion criteria apply.
排除标准
- •Previous clinically significant decompensation events (e.g. ascites [more than perihepatic ascites], VH and / or overt / apparent HE), History of other forms of chronic liver disease (e.g. alcohol-related liver disease (ARLD), autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilson’s disease, haemachromatosis, alpha-1 antitrypsin [A1At] deficiency), Patients without adequate treatment for HBV, HCV or NASH as per local guidance (e.g. antiviral therapy for chronic HBV or HCV infection or lifestyle modification in NASH) - if received curative anti-viral therapy for HCV, no sustained virological response (SVR) or SVR sustained for less than 2 years prior to screening or if HCV RNA detectable - If receiving anti-viral therapy for HBV, less than 6 months on a stable dose prior to screening, with planned dose change during the trial or HBV DNA detectable - Weight change = 5% within 6 months prior screening, Must take, or wishes to continue the intake of, restricted concomitant therapy or any concomitant therapy considered likely (based on Investigator judgement) to interfere with the safe conduct of the trial, SBP < 100 mmHg and DBP < 70 mmHg at screening, Model of End-stage Liver Disease (MELD) score of > 15 at screening, calculated by the central laboratory, Hepatic impairment defined as a Child-Turcotte-Pugh score = B8 at screening, calculated by the site, using central laboratory results, ALT or AST > 5 times upper limit of normal (ULN) at screening, measured by the central laboratory, Further exclusion criteria apply.
研究者
相似试验
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-ATBoehringer-Ingelheim RCV GmbH & Co KG80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-DKBoehringer Ingelheim B. V.80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-DEBoehringer Ingelheim Pharma GmbH & Co. KG - Clinical Research Germany80
招募中
2 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)Patients with CSPH in compensated cirrhosis due to HBV, HCV, and NASH with or without T2DMJPRN-jRCT2031220376Kutsunai Mitsuru5
尚未招募
2 期
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis.Clinical significant portal hypertension (CSPH)high blood pressure in portal vein10057166NL-OMON53952Boehringer Ingelheim5